et al,5 respectively. To identify the IVS 1 (-13T-*G) mutation, two PCR primer sets were designed, based on the amplification refractory mutation system (ARMS) described by Newton et al.6 The first set amplifies specifically the wild type allele, the second set the IVS1(-13T-G) allele (figure) . The frequencies of the three mutant alleles are given in table 1. Our data confirm those of Huie et al who found that IVS1(-13T-G) is a frequent mutation in adult GSD II, but is not associated with infantile GSD II. Further, we have shown the IVS1(-13T-*G) mutation in juvenile GSD II. The mutation was not encountered in a total of 54 unrelated controls. The other two mutations are not restricted to certain phenotypes and are more frequent in the Dutch than in other patient populations. This could be the result of a founder effect. By screening for these three mutations, we succeeded in identifying one mutant oa glucosidase allele in 42 of 121 patients (35% of the total and 49% of the Dutch patient population). In an additional 27 patients, both alleles were identified (22% of the total and 39% of the Dutch patient population) allowing a genotype-phenotype correlation to be made (table 2) .
Homozygotes for Aexon18 or AT525 and compound heterozygotes for these mutant alleles have the infantile form of GSD II and no oa-glucosidase activity. In contrast, patients with either Aexonl8 or AT525 in combination with IVS1 (-13T -*G) have the juvenile (one patient) or the adult (15 patients) phenotype and have 10 to 20% of the mean a-glucosidase activity in normal controls, suggesting that IVS 1 (-13T-*G) is a mild mutation allowing oa-glucosidase synthesis and function at 20-40% of the normal level. Homozygotes for IVS 1 (-13T-+G) were not encountered, possibly because the residual activity in these subjects prevents clinical signs.
We propose that these data are good evidence of genotype-phenotype correlations in GSD II and suggest that genotype analysis may complement routine (prenatal) diagnosis, particularly when common mutations can be identified. Further, carrier detection in couples at risk becomes a practicable option. It is unclear why parents should be seen as having this responsibility for childhood onset, but not adult onset, conditions. Parenting is about building the basis for happy and fulfilled adult lives, not just about doing the best within childhood.
We agree with GIG that "it is both possible to draw up standard, basic, guidelines for testing, and also necessary to do so if best practice is to survive the extra burdens that will result from the expansion of the field." However, this raises the question of the basis upon which such guidelines are to be developed. One key element is the contribution of all relevant perspectives, which should include affected families, voluntary organisations such as GIG, and the general public as well as professionals. But all of these perspectives should be informed by data beyond personal experience.
One of the best ways to resolve these questions is to collect evidence through systematic studies. ' 
